ReviewJournal of ovarian research2025
Advances in ovarian cancer: biological insights, therapeutic innovations, and future perspectives.
Review in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Methotrexate Alters Nrf2/HO-1 Protein Expression and Intrinsic Apoptosis-Associated Protein Responses in OVCAR-3 Ovarian Cancer Cells: Differential Modulation by Antioxidant Compounds.Journal of biochemical and molecular toxicology · 2026Article
- Discovery and Development of a TGFβ3/IL-13 Plasma Risk Score for Preoperative Discrimination of Benign and Malignant Ovarian Adnexal Masses.Diagnostics (Basel, Switzerland) · 2026Article
- Deciphering the potential pathogenic mechanisms of 3-BHA in ovarian cancer through integrated bioinformatics and machine learning strategies.Discover oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Ovarian cancer (OC) remains a highly lethal gynecologic malignancy characterized by substantial molecular heterogeneity and diagnostic challenges. Although many reviews examine specific aspects of OC biology or treatment, few attempt to connect recent findings into a broader and coherent picture. This review provides an integrated and forward-looking synthesis of emerging mechanisms and therapeutic trends in OC, understanding OC progression and therapeutic resistance. Unique contributions of this review include providing a unified interpretation of emerging multi-omics evidence that reshapes the biological understanding of individual OC histotypes, delineating key metabolic dependencies such as glutamine addiction, aberrant lipid remodeling, glycolytic plasticity and purine pathway rewiring as potential therapeutic entry points, and elucidating how ascites-driven immune dysfunction remodels antitumor immunity to ultimately influence the effectiveness of cancer vaccines, immune checkpoint blockade and adoptive cell transfer therapies. Additionally, the review articulates underexplored therapeutic intersections, including nanotechnology-enhanced immunotherapy, gene-editing nanocarriers, and microbiome-mediated modulation of drug sensitivity and immune activation. By integrating these diverse yet interconnected domains, this review proposes updated conceptual models and cross-therapeutic strategies aimed at overcoming chemoresistance and advancing precision, personalized treatment paradigms in OC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.